SOUTH SAN FRANCISCO, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today
announced an oral presentation on vosaroxin at the 21st Congress of the European Hematology Association (EHA) to be held
June 9-12, 2016 at the Bella Center in Copenhagen, Denmark.
The details for the oral presentation are as follows:
Date & Time: Saturday, June 11, 2016, 5:00 p.m. to 5:15 p.m. Central European Time
Poster Title: Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (PTS) with acute
myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Abstract Number: S505
Session Title: New Compounds in AML Treatment
Location: Hall A3
The full abstract can be viewed here.
The company will also publish data that will be on display as an E-poster:
Date & Time: Friday, June 10, 9:30 a.m. - Sunday, June 12, 11:00 a.m. Central European Time
Poster Title: Characterization of patients with relapsed or refractory AML in continued follow-up after treatment
with vosaroxin/cytarabine vs placebo/cytarabine in the VALOR trial
Abstract Number: E930
Location: E-Poster Screens
The full abstract can be viewed here.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in
Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients
aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the
clinic.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
